Kura腫瘤學 KURA 深 滬
等待開盤 10-02 09:30:00 美东时间
9.115
+0.265
+2.99%
華盛通- 最 高9.27
- 今 開8.94
- 成交量 106.37万股
- 最 低 8.90
- 昨 收 8.85
- 總市值 7.91亿
- 52周最高 19.7283
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.41
- 委 比 -20.79%
- 總股本 8679.72万
- 歷史最高 43.00
- 量 比 0.65
- 振 幅 4.18%
- 歷史最低 2.50
- 每 手 1
- 風險率 4.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Kura Oncology and Kyowa Kirin have initiated the first patient dosing in a cohort of the KOMET-007 clinical trial, evaluating ziftomenib, an investigational menin inhibitor, in combination with cytarabine and daunorubicin, along with quizartinib, for patients with newly diagnosed FLT3/NPM1 co-mutated acute myeloid leukemia (AML). Despite advances in FLT3 inhibitors, patients with FLT3/NPM1 co-mutations face high relapse rates and limited treatmen...
10-01 11:01
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)
Kura Oncology and Kyowa Kirin announced the initiation of the KOMET-017 clinical trial to evaluate ziftomenib, a menin inhibitor, in combination with intensive and non-intensive regimens for newly diagnosed <em>NPM1</em>-mutated or <em>KMT2A</em>-rearranged acute myeloid leukemia (AML). The trial comprises two Phase 3 studies with dual-primary endpoints: intensive chemotherapy trial assessing MRD-negative complete response (CR) and event-free sur...
09-29 20:01
Kura Oncology Announces The Journal Of Clinical Oncology Published The Full Results From The Pivotal KOMET-001 Clinical Trial Evaluating Ziftomenib; KOMET-001 In R/r Npm1-m AML Met Its Primary Endpoint With Ziftomenib Monotherapy Demonstrating Significant Clinical Benefit And Deep Responses
SAN DIEGO and TOKYO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA) and Kyowa Kirin Co., Ltd.
09-26 05:25
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
KOMET-001 trial demonstrates significant clinical benefit of ziftomenib in relapsed/refractory NPM1-m AML, meeting primary endpoint with 22% complete remission rate. The drug shows consistent activity across subgroups, favorable safety profile, and no significant QTc prolongation or myelosuppression. FDA Priority Review with PDUFA date set for November 30, 2025. Currently, no approved therapy targets NPM1-m AML.
09-25 21:18
Kura Oncology Showcases Preclinical Data Targeting Resistance Pathways, Highlights KO-2806 Combo Potential Ahead Of ESMO 2025
Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs)Preliminary clinical data and
09-17 04:02
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
Kura Oncology hosted an analyst/investor event to highlight the potential of KO-2806 (darlifarnib), a next-generation farnesyl transferase inhibitor (FTI), in combination with PI3Kα inhibitors, KRAS inhibitors, and antiangiogenic tyrosine kinase inhibitors (TKIs). The event showcased preclinical data demonstrating KO-2806's ability to enhance anti-tumor activity, overcome resistance mechanisms, and re-sensitize tumors to targeted therapies. Preli...
09-16 20:01
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB) stock moved upwards by 7.7% to $2...
09-10 05:06
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth
Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential.
09-05 03:17
